102 related articles for article (PubMed ID: 192508)
61. [Blood iron and ferritin in the monitoring of Hodgkin's disease].
Garavelli PL
Minerva Med; 1988 Apr; 79(4):263-4. PubMed ID: 3368104
[TBL] [Abstract][Full Text] [Related]
62. Postnatal changes in plasma ceruloplasmin and transferrin antioxidant activities in preterm babies.
Lindeman JH; Lentjes EG; van Zoeren-Grobben D; Berger HM
Biol Neonate; 2000; 78(2):73-6. PubMed ID: 10970997
[TBL] [Abstract][Full Text] [Related]
63. [Mechanism of dibunol (butylated hydroxytoluene) prolongation of life].
Kol'tover VK; Gorban' EN; Maĭor PS
Dokl Akad Nauk SSSR; 1984; 277(2):497-500. PubMed ID: 6090086
[No Abstract] [Full Text] [Related]
64. [Behavior and prognostic significance of serum ceruloplasmin in relation to the histopathological aspect of Hodgkin's disease].
Pisi E; Di Feliciantonio R; Figus E; Ferri S
Minerva Med; 1968 Feb; 59(17):944-52. PubMed ID: 5652623
[No Abstract] [Full Text] [Related]
65. [Study of the erythrocyte sedimentation rate in patients with malignant lymphogranulosis].
LAVEDAN J
Acta Unio Int Contra Cancrum; 1952; 8(2):548-52. PubMed ID: 13007575
[No Abstract] [Full Text] [Related]
66. [Ceruloplasmin-transferrin antioxidant system in in experimental and clinical atherosclerosis].
Asetskaia IL; Egorov DIu; Kozlov Av; Nalivaĭko ES; Markin SS; Sergienko VI; Azizova OA; Vladimirov IuA; Lopukhin IuM
Vestn Akad Med Nauk SSSR; 1990; (12):41-5. PubMed ID: 2291327
[TBL] [Abstract][Full Text] [Related]
67. Survival after recurrence: prognostic factors and spread patterns in clinical stages I and II of Hodgkin's disease.
Tubiana M; van der Werf-Messing B; Laugier A; Hayat M; Henry-Amar M; Attie E; Leroy T
Natl Cancer Inst Monogr; 1973 May; 36():513-30. PubMed ID: 4744607
[No Abstract] [Full Text] [Related]
68. The erythrocyte sedimentation rate as a monitor for relapse in patients with previously treated Hodgkin's disease.
Le Bourgeois JP; Tubiana M
Int J Radiat Oncol Biol Phys; 1977; 2(3-4):241-7. PubMed ID: 863759
[No Abstract] [Full Text] [Related]
69. Prognostic markers of disease activity in Hodgkin's disease.
Martinow AJ; Yuen K; Cooper IA; Matthews JP; Juneja S; Wolf M; Januszewicz H; Prince HM
Leuk Lymphoma; 1998 Apr; 29(3-4):383-9. PubMed ID: 9684935
[TBL] [Abstract][Full Text] [Related]
70. [Determination of alkaline phosphatase isoenzymes in the definition of the clinical stage of Hodgkin's disease].
Lauria F; Casanova R; Baccarani M; Tura S
Haematologica; 1972; 57(9):543-6. PubMed ID: 4199309
[No Abstract] [Full Text] [Related]
71. [Blood copper and ceruloplasmin levels in hemolymphopathies. I. Malignant lymphoma].
Tura S; Bernardi L; Baccarani M; Sanguinetti F; Branzi A
G Clin Med; 1968 Nov; 49(11):1090-104. PubMed ID: 5757473
[No Abstract] [Full Text] [Related]
72. Serum alpha-1-acid-glycoprotein, haptoglobin and C3 in Hodgkin's disease. A comparison with other acute-phase indicators.
Gobbi PG; Merlini G; Parrinello GA; Cavalli P; Ascari E
Acta Haematol; 1982; 67(4):255-62. PubMed ID: 6180585
[TBL] [Abstract][Full Text] [Related]
73. [Iron, copper, cobalt, zinc and various metalloprotein concentrations in the blood of patients with acute cholecystitis].
Kovalev MM; Kikot' VA
Vrach Delo; 1969; 12():17-21. PubMed ID: 5375622
[No Abstract] [Full Text] [Related]
74. The activity of neutrophil myeloperoxidase in patients with Hodgkin's disease.
Dabrowska M; Kemona H; Prokopowicz J; Dabrowski A; Kiluk S
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(6):817-21. PubMed ID: 1713888
[TBL] [Abstract][Full Text] [Related]
75. [Studies on behavior of trace metal and carrier protein in patients with cancer --behavior of zinc, copper, iron, ceruloplasmin and transferrin in blood (author's transl)].
Morita N; Shingami T; Nakao Y; Yunoki K
Igaku Kenkyu; 1979 Sep; 49(3):277-82. PubMed ID: 547644
[No Abstract] [Full Text] [Related]
76. [Ceruloplasmin, transferrin and insulin blood levels in those with diabetes mellitus type II and in nondiabetics who participated in the clean-up after the Chernobyl accident].
Zueva NA; Iukhimuk LN; Gerasimenko TI; Kovalenko AN; Efimov AS
Lik Sprava; 2001; (3):14-6. PubMed ID: 11560002
[TBL] [Abstract][Full Text] [Related]
77. [Ceruloplasmin and immunoglobulins under controlled D-penicillamine therapy in rheumatoid arthritis].
Schmidt KL; Ott VR
Z Rheumatol; 1976; 35(3-4):154-63. PubMed ID: 1266422
[TBL] [Abstract][Full Text] [Related]
78. [The use of EPR spectroscopy to control the changes in organism radioresistance. Clinical results].
Pulatova MK; Sharygin VL; Shliakova TG; Sipiagina AE; Vasserman AM
Biofizika; 2009; 54(2):323-33. PubMed ID: 19402545
[TBL] [Abstract][Full Text] [Related]
79. Leucocyte zinc in non-Hodgkin's lymphoma and Hodgkin's disease.
Field HP; Jones R; Walker BE; Kelleher J; Simmons AV
Nutr Cancer; 1988; 11(2):83-92. PubMed ID: 3362723
[TBL] [Abstract][Full Text] [Related]
80. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
Josting A; Franklin J; May M; Koch P; Beykirch MK; Heinz J; Rudolph C; Diehl V; Engert A
J Clin Oncol; 2002 Jan; 20(1):221-30. PubMed ID: 11773173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
